Discrimination of Alzheimer patients responding to cholinesterase inhibitor therapy.
We have studied whether it is possible to discriminate responders to tacrine treatment from patients nonresponsive to tacrine in Alzheimer's disease. The results indicate that mildly demented patients will most likely gain a benefit of tacrine treatment. Neuropsychological tests on attention and working memory after a single dose of tacrine might be useful as well as a single dose pharmaco-EEG in discriminating responders to treatment.
Alhainen
K
K
Department of Neurology, University of Kuopio, Finland.
Riekkinen
P J
PJ
D000368:Aged; D000544:Alzheimer Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D001288:Attention / Q000187:drug effects; D015306:Biogenic Monoamines / Q000134:cerebrospinal fluid / Q000378:metabolism; D002800:Cholinesterase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008568:Memory / Q000187:drug effects*; D009483:Neuropsychological Tests; D013004:Somatostatin / Q000134:cerebrospinal fluid / Q000378:metabolism; D013619:Tacrine / Q000494:pharmacology* / Q000627:therapeutic use*; D016896:Treatment Outcome
D015306:Biogenic Monoamines; D002800:Cholinesterase Inhibitors; D013619:Tacrine; D013004:Somatostatin